Do you treat retroperitoneal sarcomas with a boost to the rind (or suspected close surgical margin)?  

If so, what patients do you select for the boost? And what data do you give to adequately satisfy the insurance review and win approval?



Answer from: Radiation Oncologist at Academic Institution